BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19707244)

  • 1. Controlling the cost of innovative cancer therapeutics.
    Malik NN
    Nat Rev Clin Oncol; 2009 Sep; 6(9):550-2. PubMed ID: 19707244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of Current Policy Strategies to Reduce US Cancer Drug Costs.
    Green AK; Ohn JA; Bach PB
    J Clin Oncol; 2020 Feb; 38(4):372-379. PubMed ID: 31804856
    [No Abstract]   [Full Text] [Related]  

  • 4. Market spiral pricing of cancer drugs.
    Light DW; Kantarjian H
    Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of pricing strategy on the costs of oral anti-cancer drugs.
    Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
    Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soaring price of cancer drugs leads plans to new approaches.
    Sipkoff M
    Manag Care; 2007 Aug; 16(8):12-3. PubMed ID: 17886533
    [No Abstract]   [Full Text] [Related]  

  • 7. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empower physicians to fight financial toxicity with biosimilars.
    Oubre K
    Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP374-SP375. PubMed ID: 31860250
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenging the soaring price of cancer medicines: a call for equity and transparency.
    Gonçalves A; Maraninchi D; Vernant JP
    Ann Oncol; 2016 Sep; 27(9):1812-3. PubMed ID: 27154419
    [No Abstract]   [Full Text] [Related]  

  • 10. Why clinical oncologists should talk about the price of cancer drugs.
    Berlinger N
    Virtual Mentor; 2013 Aug; 15(8):677-80. PubMed ID: 23937783
    [No Abstract]   [Full Text] [Related]  

  • 11. Affordability of Cancer Drugs in Sub-Saharan Africa: Effects of Pricing on Needless Loss of Life.
    Martei YM; Binagwaho A; Shulman LN
    JAMA Oncol; 2017 Oct; 3(10):1301-1302. PubMed ID: 28426846
    [No Abstract]   [Full Text] [Related]  

  • 12. "It's the economy, stupid": strategies for improved cost containment in cancer treatment.
    Sleijfer S
    Clin Pharmacol Ther; 2014 Apr; 95(4):365-7. PubMed ID: 24646487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
    Prasad V; Mailankody S
    Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer drugs in China: affordability and creativity.
    The Lancet
    Lancet; 2018 May; 391(10133):1866. PubMed ID: 29781431
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments.
    Aguiar PN; Adashek JJ; Roitberg F; Noia Barreto CM; Del Giglio A; Lopes GL
    Value Health Reg Issues; 2019 Dec; 20():47-50. PubMed ID: 30856543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overspending driven by oversized single dose vials of cancer drugs.
    Bach PB; Conti RM; Muller RJ; Schnorr GC; Saltz LB
    BMJ; 2016 Feb; 352():i788. PubMed ID: 26932932
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars.
    Henry D; Taylor C
    Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health policy: Putting a price on cancer.
    Sullivan R; Aggarwal A
    Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
    [No Abstract]   [Full Text] [Related]  

  • 20. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.